Both low and high serum IGF-1 levels associate with increased risk of cardiovascular events in elderly men

Journal of Clinical Endocrinology and Metabolism

Volumn 99, Issue 11, 2014, Pages E2308-E2316

  Carlzon, Daniel ^a   Svensson, Johan ^a   Petzold, Max ^a   Karlsson, Magnus K ^b   Ljunggren, Östen ^c   Tivesten, Asa ^d   Mellström, Dan ^a   Ohlsson, Claes ^a  

^a UNIVERSITY OF GOTHENBURG   (Sweden)

^b LUND UNIVERSITY HOSPITAL   (Sweden)

^c UPPSALA UNIVERSITY   (Sweden)

^d UNIVERSITY OF GOTHENBURG   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

APOLIPOPROTEIN A1; APOLIPOPROTEIN B; SOMATOMEDIN C;

AGED; ARTICLE; BODY MASS; CARDIOVASCULAR RISK; CEREBROVASCULAR DISEASE; CONTROLLED STUDY; DIABETES MELLITUS; DISEASE ASSOCIATION; HUMAN; HYPERTENSION; ISCHEMIC HEART DISEASE; MAJOR CLINICAL STUDY; MALE; MEDICAL HISTORY; PHYSICAL ACTIVITY; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; RISK FACTOR; SMOKING; SWEDEN; BLOOD; CARDIOVASCULAR DISEASES; INCIDENCE; METABOLISM; PREVALENCE; PROSPECTIVE STUDY; REGISTER; RISK; VERY ELDERLY;

AGED; AGED, 80 AND OVER; CARDIOVASCULAR DISEASES; HUMANS; INCIDENCE; INSULIN-LIKE GROWTH FACTOR I; MALE; PREVALENCE; PROSPECTIVE STUDIES; REGISTRIES; RISK; SWEDEN;

EID: 84910020575     PISSN: 0021972X     EISSN: 19457197     Source Type: Journal    
DOI: 10.1210/jc.2014-1575     Document Type: Article

References (38)

1. Ohlsson C, Mohan S, Sjögren K, et al. The role of liver-derived insulin-like growth factor-I. Endocr Rev. 2009; 30: 494-535.
2. Samani AA, Yakar S, LeRoith D, Brodt P. The role of the IGF system in cancer growth and metastasis: Overview and recent insights. Endocr Rev. 2007; 28: 20-47.
3. Sesmilo G, Biller BM, Llevadot J, et al. Effects of growth hormone administration on inflammatory and other cardiovascular risk markers in men with growth hormone deficiency. A randomized, controlled clinical trial. Ann Intern Med. 2000; 133: 111-122.
4. Succurro E, Andreozzi F, Sciacqua A, et al. Reciprocal association of plasma IGF-1 and interleukin-6 levels with cardiometabolic risk factors in nondiabetic subjects. Diabetes Care. 2008; 31: 1886-1888.
5. Lamberts SW, van den Beld AW, van der Lely AJ. The endocrinology of aging. Science. 1997; 278: 419-424.
6. Sjögren K, Liu JL, Blad K, et al. Liver-derived insulin-like growth factor I (IGF-1) is the principal source of IGF-1 in blood but is not required for postnatal body growth in mice. Proc Natl Acad Sci U S A. 1999; 96: 7088-7092.
7. Yakar S, Liu JL, Stannard B, et al. Normal growth and development in the absence of hepatic insulin-like growth factor I. Proc Natl Acad Sci U S A. 1999; 96: 7324-7329.
8. Juul A, Scheike T, Davidsen M, Gyllenborg J, Jorgensen T. Low serum insulin-like growth factor I is associated with increased risk of ischemic heart disease: a population-based case-control study. Circulation. 2002; 106: 939-944.
9. Ruidavets JB, Luc G, Machez E, et al. Effects of insulin-like growth factor 1 in preventing acute coronary syndromes: The PRIME study. Atherosclerosis. 2011; 218: 464-469.
10. Vaessen N, Heutink P, Janssen JA, et al.Apolymorphism in the gene for IGF-1: Functional properties and risk for type 2 diabetes and myocardial infarction. Diabetes. 2001; 50: 637-642.
11. Kaplan RC, McGinn AP, Pollak MN, et al. Association of total insulin-like growth factor-I, insulin-like growth factor binding protein- 1 (IGFBP-1), and IGFBP-3 levels with incident coronary events and ischemic stroke. J Clin Endocrinol Metab. 2007; 92: 1319-1325.
12. Johnsen SP, Hundborg HH, Sorensen HT, et al. Insulin-like growth factor (IGF) I, -II, and IGF binding protein-3 and risk of ischemic stroke. J Clin Endocrinol Metab. 2005; 90: 5937-5941.
13. Laughlin GA, Barrett-Connor E, Criqui MH, Kritz-Silverstein D. The prospective association of serum insulin-like growth factor I (IGF-1) and IGF-binding protein-1 levels with all cause and cardiovascular disease mortality in older adults: The Rancho Bernardo Study. J Clin Endocrinol Metab. 2004; 89: 114-120.
14. Svensson J, Carlzon D, Petzold M, et al. 2012 Both Low and High Serum IGF-1 Levels Associate with Cancer Mortality in Older Men. J Clin Endocrinol Metab.
15. van Bunderen CC, van Nieuwpoort IC, van Schoor NM, Deeg DJ, Lips P, Drent ML. The association of serum insulin-like growth factor-I with mortality, cardiovascular disease, and cancer in the elderly: A population-based study. J Clin Endocrinol Metab. 2010; 95: 4616-4624.
16. Friedrich N, Haring R, Nauck M, et al. Mortality and serum insulinlike growth factor (IGF)-I and IGF binding protein 3 concentrations. J Clin Endocrinol Metab. 2009; 94: 1732-1739.
17. van BunderenCC, OosterwerffMM, van Schoor NM, Deeg DJ, Lips P, Drent ML. Serum IGF1, metabolic syndrome, and incident cardiovascular disease in older people: A population-based study. Eur J Endocrinol. 2013; 168: 393-401.
18. Rosén T, Bengtsson BA. Premature mortality due to cardiovascular disease in hypopituitarism. Lancet. 1990; 336: 285-288.
19. Svensson J, Bengtsson BA, Rosén T, Oden A, Johannsson G. Malignant disease and cardiovascular morbidity in hypopituitary adults with or without growth hormone replacement therapy. J Clin Endocrinol Metab. 2004; 89: 3306-3312.
20. Tomlinson JW, Holden N, Hills RK, et al. Association between premature mortality and hypopituitarism. West Midlands Prospective Hypopituitary Study Group. Lancet. 2001; 357: 425-431.
21. Andreassen M, Raymond I, Kistorp C, Hildebrandt P, Faber J, Kristensen LØ. IGF1 as predictor of all cause mortality and cardiovascular disease in an elderly population. Eur J Endocrinol. 2009; 160: 25-31.
22. Jansson JO, Edén S, Isaksson O. Sexual dimorphism in the control of growth hormone secretion. Endocr Rev. 1985; 6: 128-150.
23. Mellström D, Johnell O, Ljunggren O, et al. Free testosterone is an independent predictor of BMD and prevalent fractures in elderly men: MrOS Sweden. J Bone Miner Res. 2006; 21: 529-535.
24. Orwoll E, Blank JB, Barrett-Connor E, et al. Design and baseline characteristics of the osteoporotic fractures in men (MrOS) study-a large observational study of the determinants of fracture in older men. Contemp Clin Trials. 2005; 26: 569-585.
25. Merlo J, Lindblad U, Pessah-Rasmussen H, et al. Comparison of different procedures to identify probable cases of myocardial infarction and stroke in two Swedish prospective cohort studies using local and national routine registers. Eur J Epidemiol. 2000; 16: 235-243.
26. Durrleman S, Simon R. Flexible regression models with cubic splines. Stat Med. 1989; 8: 551-561.
27. Claeskens G HN. 2008 Cambridge series in statistical and probabalistic mathematics: Model selection and model averaging. Cambridge, UK: Cambridge University Press
28. Janssen JA, Stolk RP, Pols HA, Grobbee DE, Lamberts SW. Serum total IGF-1, free IGF-1, and IGFB-1 levels in an elderly population: Relation to cardiovascular risk factors and disease. Arterioscler Thromb Vasc Biol. 1998; 18: 277-282.
29. Brugts MP, van den Beld AW, Hofland LJ, et al. Low circulating insulin-like growth factor I bioactivity in elderly men is associated with increased mortality. J Clin Endocrinol Metab. 2008; 93: 2515-2522.
30. Burgers AM, Biermasz NR, Schoones JW, et al. Meta-analysis and dose-response metaregression: Circulating insulin-like growth factor I (IGF-1) and mortality. J Clin Endocrinol Metab. 2011; 96: 2912-2920.
31. Vasan RS, Sullivan LM, D'Agostino RB, et al. Serum insulin-like growth factor I and risk for heart failure in elderly individuals without a previous myocardial infarction: The Framingham Heart Study. Ann Intern Med. 2003; 139: 642-648.
32. Yeap BB, Chubb SA, McCaul KA, et al. Associations of IGF1 and IGFBPs 1 and 3 with all-cause and cardiovascular mortality in older men: The Health In Men Study. Eur J Endocrinol. 2011; 164: 715-723.
33. BögerRH, Skamira C, Bode- BögerSM, Brabant G, von zur Muhlen A, Frolich JC. Nitric oxide may mediate the hemodynamic effects of recombinant growth hormone in patients with acquired growth hormone deficiency. A double-blind, placebo-controlled study. J Clin Invest. 1996; 98: 2706-2713.
34. Sherlock M, Ayuk J, Tomlinson JW, et al. Mortality in patients with pituitary disease. Endocr Rev. 2010; 31: 301-342.
35. Clayton RN. Cardiovascular function in acromegaly. Endocr Rev. 2003; 24: 272-277.
36. Colao A, Ferone D, Marzullo P, Lombardi G. Systemic complications of acromegaly: Epidemiology, pathogenesis, and management. Endocr Rev. 2004; 25: 102-152.
37. Paisley AN, Banerjee M, Rezai M, et al. Changes in arterial stiffness but not carotid intimal thickness in acromegaly. J Clin Endocrinol Metab. 2011; 96: 1486-1492.
38. Saccà L, Cittadini A, Fazio S. Growth hormone and the heart. Endocr Rev. 1994; 15: 555-573.